The cure of multiple sclerosis is a one of the major issues in management of this chronic disorder. There are no drugs invented to completely cure all the symptoms associated with Multiple Sclerosis.
âThe FDA has approved seven treatments that target myelin repair and neuroprotection including Î²-interferon products marketed as Betaferon, Avonex or Rebif, glatiramer acetate (Copaxone), natalizumba (Tysabri), fingolimod (Gilenya) and mitozantrone (Novantrone). Many of these therapies carry warnings of serious and possibly life-threatening side effects. Two of the most widely used therapies are the oral compound fingolimod and Copaxone. Gilenyaâ¢ (fingolimod) is a sphyingosine 1-phophate receptor modulator that prevents migration of lymphocytes from the periphery to CNS, and has shown promise for reducing the number of relapses. Copaxone (glatimer acetate) is a synthetic peptide that imitates myelin proteins, but the mechanism of action is unknown. Because MS has an onset during the reproductive period in a womenâs life, concerns over treatment and pregnancy have been addressed. Many of the treatments have not been studied in laboratory settings with pregnant animals. Moreover, current treatment regimens are expensive (~$30,000/year), and compliance is often marginal. Thus there is a need for disease-modifying therapies that are non-toxic and inexpensive Zagon IS, Endogenous Opioids and the Treatment of Multiple Sclerosis.
Journal of Multiple sclerosis focuses mainly on drug discovery in multiple sclerosis since this is a major thrust area of research. This open access journal is trying to make the readers aware about the adverse effects of various drugs used in multiple sclerosis treatment.
Last date updated on April, 2021